• Zentalis Pharmaceuticals Inc ZNTL.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -93 cents. The mean expectation of eleven analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -99 cents to -47 cents per share.

• Revenue was $26.87 million​; analysts expected zero.

• Zentalis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 67 cents​.

• The company reported a quarterly loss of $47.47 million.

• Zentalis Pharmaceuticals Inc shares had fallen by 38.3% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 10.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $7.00

This summary was machine generated from LSEG data March 26 at 08:53 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)